2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Aurora Kinase

Aurora Kinase

Aurora Kinase

Related Products

PDF 0.27 MB

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Aurora Kinase Isoform Specific Products:

Aurora Kinase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS01272
    Aurkb Rat Pre-designed siRNA Set A
    		Inhibitor

    Aurkb Rat Pre-designed siRNA Set A contains three designed siRNAs for Aurkb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Aurkb Rat Pre-designed siRNA Set A
  • HY-RS01267
    Aurka Mouse Pre-designed siRNA Set A
    		Inhibitor

    Aurka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Aurka Mouse Pre-designed siRNA Set A
  • HY-123610
    BRD-7880
    		Inhibitor
    BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC50 values of 7 nM and 12 nM, respectively.
    BRD-7880
  • HY-175982
    AURKA-IN-3
    		Inhibitor
    AURKA-IN-3 (Compound AL8) is an irreversible covalent Aurora kinase A (AURKA) inhibitor with an IC50 value of 23.0 nM. AURKA-IN-3 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by AURKA, and reduces the autophosphorylation level of AURKA. AURKA-IN-3 is promising for research of malignant tumors associated with high AURKA expression (e.g., leukemia, lymphoma).
    AURKA-IN-3
  • HY-175526
    Aurora kinase ligand-1
    Aurora kinase ligand-1 (Compound I-4) is an Aurora kinase B (AURKB) PROTAC ligand. Aurora kinase ligand-1 can be conjugated with E3 ligase Ligand (HY-112078) and linker to synthesize AURKB PROTAC degrader MS44 (HY-175525). MS44 can be used for cancer research.
    Aurora kinase ligand-1
  • HY-N1168
    Tenacigenin B
    		Modulator
    Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of Aurora-A.
    Tenacigenin B
  • HY-175827
    MK-5108-NH-PEG2-alkyne
    		Inhibitor
    MK-5108-NH-PEG2-alkyne is a Aurora kinase A (AURKA) inhibitor. MK-5108-NH-PEG2-alkyne can be used for synthesis of PROTAC AURKA degrader 1 (HY-175830).
    MK-5108-NH-PEG2-alkyne
  • HY-125158
    HOI-07
    		Inhibitor
    HOI-07 is a selective Aurora B kinase inhibitor. HOI-07 blocks phosphorylation of histone H3 on Ser10 in lung cancer cells. HOI-07 induces cell-cycle arrest, and apoptosis. HOI-07 has antitumor activity, and suppresses the tumor growth of A549, 143B and KHOS xenografts.
    HOI-07
  • HY-RS01268
    Aurka Rat Pre-designed siRNA Set A
    		Inhibitor

    Aurka Rat Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Aurka Rat Pre-designed siRNA Set A
  • HY-12476
    SAR156497
    		Inhibitor
    SAR156497 (compound 47) is an Aurora inhibitor, with IC50 values ​​of 0.6 nM and 1 nM for Aurora A and Aurora B, respectively. SAR156497 can also inhibit PDE3, with IC50 value of 4 μM. SAR156497 can be used in anticancer research.
    SAR156497
  • HY-167854
    KW-2450 free base
    		Inhibitor
    KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.
    KW-2450 free base
  • HY-175525
    MS44
    		Degrader
    MS44 is a potent aurora kinase B (AURKB PROTAC) degrader (DC50 = 103 nM). MS44 effectively degrades AURKB in a time- and ubiquitin-proteasome system (UPS)-dependent manner and is selective for AURKB over AURKA and AURKC. MS44 effectively inhibits the proliferation in multiple cancer cell lines and potently induces G2/M arrest. MS44 can be used for the study of AURKB-dependent tumors (Pink: Target protein ligand (HY-175526); Blue: E3 ligand (HY-112078); Black: Linker; E3 ligand + Linker (HY-132938)).
    MS44
  • HY-12201A
    TAK-901 hydrochloride
    		Inhibitor
    TAK-901 hydrochloride is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
    TAK-901 hydrochloride
  • HY-164455
    AJI-214
    		Inhibitor
    AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD).
    AJI-214
  • HY-10180R
    MLN8054 (Standard)
    		Inhibitor
    MLN8054 (Standard) is the analytical standard of MLN8054. This product is intended for research and analytical applications. MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054 (Standard)
  • HY-160447
    FAK/Aurora kinase-IN-1
    		Inhibitor
    FAK/Aurora kinase-IN-1 is a FAK and aurora kinase inhibitor with IC50 values of 6.61 nM and 0.91 nM, respectively. FAK/Aurora kinase-IN-1 shows anticancer effects (WO2018019252A1; compound 11).
    FAK/Aurora kinase-IN-1
  • HY-122370A
    Tripolin B
    		Inhibitor
    Tripolin B is an ATP-competitive Aurora kinase inhibitor with IC50 values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells.
    Tripolin B
  • HY-10179R
    Danusertib (Standard)
    		Inhibitor
    Danusertib (Standard) is the analytical standard of Danusertib. This product is intended for research and analytical applications. Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
    Danusertib (Standard)
  • HY-121895
    BI 831266
    		Inhibitor
    BI 831266 is a potent and selective inhibitor of Aurora kinase B with antitumor activity.
    BI 831266
  • HY-13072B
    Cenisertib benzoate
    		Inhibitor
    Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.
    Cenisertib benzoate
Cat. No. Product Name / Synonyms Application Reactivity
Aurora Kinase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.